What is the most promising treatment for glioblastoma?

A clinical trial has found that selinexor, the first of a new class of anti-cancer drugs, was able to shrink tumors in almost a third of patients with recurrent glioblastoma, an aggressive brain cancer.

What is the success rate of radiation therapy for glioblastoma?

Among GBM patients, overall response rate was 50% with a 6-month progression-free survival of 65%. Median overall survival was 12.5 months and 1-year survival was 54%.

Is there any hope for glioblastoma?

The trial advances basic science research on the relationship between purine levels and treatment resistance to develop new treatment options for patients.

Why is glioblastoma incurable?

To date GBM remains incurable due to its heterogeneity and complex pathogenesis. Continued research efforts will help to provide better treatment options to combat the disease in future.

How fast does glioblastoma grow back after radiation?

However, we now know that GBM is a heterogeneous group of tumors (it behaves differently in different people) and the time when it comes back or recurs can vary. In the majority of patients it has a tendency to recur within 6-8 months.

Can radiotherapy shrink glioblastoma?

Radiation oncologist Josh Yamada is an expert in image-guided radiation therapy and other forms of treatment for people with glioma. Radiation therapy can shrink or kill tumor cells.

Can a glioblastoma go into remission?

In remission, symptoms may let up or disappear for a time. Glioblastomas often regrow. If that happens, doctors may be able to treat it with surgery and a different form of radiation and chemotherapy.

Does glioblastoma ever go into remission?

Is CD133 a cancer stem cell marker in glioblastoma?

The role of the cell surface CD133 as a cancer stem cell marker in glioblastoma (GBM) has been widely investigated, since it identifies cells that are able to initiate neurosphere growth and form heterogeneous tumors when transplanted in immune-compromised mice.

What do we know about cancer stem cells in glioblastomas?

Glioblastomas (GBM) are paradigmatic for the investigation of cancer stem cells (CSC) in solid tumors. Recently, the discovery of CD133- CSC in addition to CD133+ CSC has substantially added to our understanding of the complexity of GBM CSC.

What is the prognosis of glioblastoma?

Glioblastoma (GBM) is a heterogeneous tumor of the brain with a poor prognosis due to recurrence and drug resistance following therapy. Genome-wide profiling has revealed the existence of distinct GBM molecular subtypes that respond differently to aggressive therapies.

https://www.youtube.com/watch?v=jYns3c3ck9Q